LENEXA, Kan., July 16, 2026
Eurofins Viracor has expanded its immunology testing portfolio with the launch of three new plasma-based cytokine and chemokine assays designed to enhance immune monitoring in solid organ transplant, hematopoietic cell transplant (HCT), and other immunocompromised patients. The newly introduced assays measure CXCL9, CXCL10, and Interleukin-18 (IL-18), providing clinicians and researchers with rapid, quantitative assessment of critical T cell-mediated immune signaling biomarkers using minimally invasive EDTA plasma specimens. The expansion reflects growing demand for advanced biomarker testing that supports earlier detection of immune activation, inflammatory responses, and potential transplant complications. By offering 24-hour turnaround times and compatibility with customized cytokine testing panels, Eurofins Viracor aims to strengthen clinical decision-making while supporting personalized transplant care, immunology research, and precision diagnostic medicine.
New Plasma Assays Strengthen Immune Monitoring Capabilities
The addition of CXCL9, CXCL10, and IL-18 significantly broadens Eurofins Viracor’s cytokine testing menu, enabling healthcare providers to monitor key biomarkers involved in T helper 1 (Th1)-polarized immune responses, inflammatory signaling, and communication between the innate and adaptive immune systems. These biological pathways are increasingly recognized for their importance in allograft injury, acute transplant rejection, and chronic graft dysfunction, making accurate biomarker assessment an essential component of post-transplant patient management. The new assays provide quantitative measurements from minimally invasive plasma samples, reducing patient burden while delivering clinically relevant immune monitoring information. Each assay can be ordered individually or combined into custom cytokine panels, allowing transplant centers and clinical laboratories to tailor testing strategies according to patient needs and research objectives while maintaining standardized workflows across transplant programs.
Rapid Turnaround Supports Timely Clinical Decisions
A key advantage of the expanded testing portfolio is the ability to deliver results within 24 hours after specimen receipt for eligible submissions, enabling physicians to make faster and more informed treatment decisions for vulnerable patient populations. The assays utilize EDTA plasma collection, supported by established specimen handling, shipping, and stability protocols that simplify sample collection across healthcare settings. In addition to rapid reporting, the tests include population-based reference intervals and validated analytical performance characteristics that support consistent interpretation of immune biomarker levels. As transplant medicine increasingly adopts precision diagnostics, timely cytokine profiling offers clinicians additional insight into immune activity beyond conventional laboratory testing, helping identify patients who may require closer monitoring or therapeutic adjustments. The flexibility to integrate these biomarkers into broader immunology testing workflows also enhances research capabilities focused on transplant outcomes and immune-mediated diseases.
Advertisement
Advancing Precision Diagnostics for Transplant Medicine
With more than 40 years of expertise in infectious disease, immunology, and allergy diagnostics, Eurofins Viracor continues to expand its role in precision laboratory medicine through innovative biomarker testing solutions. The launch of these plasma assays strengthens the company’s comprehensive transplant diagnostics portfolio, supporting healthcare providers caring for patients with complex immune conditions. Growing scientific evidence continues to highlight the clinical relevance of CXCL9, CXCL10, and IL-18 as biomarkers associated with transplant rejection, inflammatory activity, and immune regulation, reinforcing their value in both clinical practice and translational research. By combining rapid turnaround, minimally invasive sample collection, and quantitative immune profiling, Eurofins Viracor is helping clinicians improve patient monitoring while advancing personalized medicine for transplant recipients and other immunocompromised populations. The expanded cytokine testing portfolio further demonstrates the company’s commitment to delivering high-quality diagnostic innovations that improve patient care through earlier detection, better disease monitoring, and more informed clinical decision-making.
Source: Eurofins Viracor press release
